Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Law & Regulation CDE Guideline Reference Listed Drug (RLD) MAH Pharmacovigilance Marketing Approval CMC Bioequivalence (BE) Post-market Generic Drug Biosimilar Cancer New DrugMonthly Recap: China Pharmaceutical Regulatory Updates | April 2022 Check out China's pharmaceutical regulation updates April 2022: China NMPA releases Pharmacovigilance Inspection Guidelines...
May 05, 2022
NRDL Volume-Based Procurement Medical Insurance Innovative Drug Generic Drug Biosimilar New Drug COVID-19Multinational Pharma Companies Record Sales Growth in 2021 Johnson & Johnson ranks the first with global sales of 93.77 billion USD. Pfizer has the most rapid growth in global sales, zooming up by 95% to 81.3 billion USD. AstraZeneca is the largest foreign pharma company regarding its 5.99 billion USD sales in China. MSD records the most vigorous sales growth in China of 60%, bringing the sales to 4.26 billion USD.
Mar 18, 2022
Law & Regulation CDE Guideline Reference Listed Drug (RLD) Marketing Approval Clinical Trial Volume-Based Procurement Generic Drug Biosimilar New DrugMonthly Recap: China Pharmaceutical Regulatory Updates | January 2022 1. China Pilots Online Sales of Prescription Drugs in Shenzhen; 2. National Insulin Procurement to Start in May; 3. China NMPA Grants Two Rx-to-OTC Switches; 4. China NMPA Releases the 50th Batch of Reference Listed Drugs; 5. China NMPA Approves 221 Medical Devices; 6. China NMPA Issues Three Industry Standards for Medical Devices; 7. Pharmaceutical Guidelines.
Feb 10, 2022
Marketing Approval Priority Review and Approval Innovative Drug Generic Drug Biological Product Biosimilar Drug Registration New DrugMonthly Report: New Drug Approvals in China | Oct. 2021 In Oct. 2021, China's NMPA granted marketing authorization approvals to 11 new drugs, including Takeda's VOCINTI and Sanofi's Clopidogrel Bisulfate and Aspirin Tablets.
Nov 08, 2021
Marketing Approval Innovative Drug Generic Drug Biological Product Biosimilar Drug Registration New DrugMonthly Report: New Drug Approvals in China | Sept. 2021 In Sept. 2021, China's NMPA granted 13 new drug approvals, including for Sanofi-Aventis Groupe's Dupilumab Injection and Merck's Pembrolizumab Injection.
Oct 25, 2021
- How to Sell OTC Drugs to China Through Cross-Border E-Commerce
- China NMPA Announces Key Points for Pharmacovigilance Inspections
- China Releases MedDRA Coding Guidance for Adverse Drug Reaction (ADR) Reports
- China Implements New Rules on Drug MAH's Annual Reports
- Beijing IP Court Rules on China's First Drug Patent Linkage Litigation Case